Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results.
Autor*in: |
Raffi, François [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2013 |
---|
Umfang: |
9 |
---|
Übergeordnetes Werk: |
Enthalten in: Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model - Berhane, S. ELSEVIER, 2016, New York, NY |
---|---|
Übergeordnetes Werk: |
volume:13 ; year:2013 ; number:11 ; pages:927-935 ; extent:9 |
Links: |
---|
DOI / URN: |
10.1016/S1473-3099(13)70257-3 |
---|
Katalog-ID: |
ELV02705943X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV02705943X | ||
003 | DE-627 | ||
005 | 20230623185234.0 | ||
007 | cr uuu---uuuuu | ||
008 | 180603s2013 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/S1473-3099(13)70257-3 |2 doi | |
028 | 5 | 2 | |a GBVA2013004000015.pica |
035 | |a (DE-627)ELV02705943X | ||
035 | |a (ELSEVIER)S1473-3099(13)70257-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 610 | |
082 | 0 | 4 | |a 610 |q DE-600 |
082 | 0 | 4 | |a 610 |q VZ |
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.44 |2 bkl | ||
100 | 1 | |a Raffi, François |e verfasserin |4 aut | |
245 | 1 | 0 | |a Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
264 | 1 | |c 2013 | |
300 | |a 9 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. | ||
700 | 1 | |a Jaeger, Hans |4 oth | |
700 | 1 | |a Quiros-Roldan, Eugenia |4 oth | |
700 | 1 | |a Albrecht, Helmut |4 oth | |
700 | 1 | |a Belonosova, Elena |4 oth | |
700 | 1 | |a Gatell, Jose M |4 oth | |
700 | 1 | |a Baril, Jean-Guy |4 oth | |
700 | 1 | |a Domingo, Pere |4 oth | |
700 | 1 | |a Brennan, Clare |4 oth | |
700 | 1 | |a Almond, Steve |4 oth | |
700 | 1 | |a Min, Sherene |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier |a Berhane, S. ELSEVIER |t Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |d 2016 |g New York, NY |w (DE-627)ELV013808834 |
773 | 1 | 8 | |g volume:13 |g year:2013 |g number:11 |g pages:927-935 |g extent:9 |
856 | 4 | 0 | |u https://doi.org/10.1016/S1473-3099(13)70257-3 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_26 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_70 | ||
936 | b | k | |a 44.44 |j Parasitologie |x Medizin |q VZ |
951 | |a AR | ||
952 | |d 13 |j 2013 |e 11 |h 927-935 |g 9 | ||
953 | |2 045F |a 610 |
author_variant |
f r fr |
---|---|
matchkey_str |
raffifranoisjaegerhansquirosroldaneugeni:2013----:nealdltgaivrutiealrlervrnniervrlavautwthvifcinpigsuy6ekeutfo |
hierarchy_sort_str |
2013 |
bklnumber |
44.44 |
publishDate |
2013 |
allfields |
10.1016/S1473-3099(13)70257-3 doi GBVA2013004000015.pica (DE-627)ELV02705943X (ELSEVIER)S1473-3099(13)70257-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Raffi, François verfasserin aut Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial 2013 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. Jaeger, Hans oth Quiros-Roldan, Eugenia oth Albrecht, Helmut oth Belonosova, Elena oth Gatell, Jose M oth Baril, Jean-Guy oth Domingo, Pere oth Brennan, Clare oth Almond, Steve oth Min, Sherene oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:13 year:2013 number:11 pages:927-935 extent:9 https://doi.org/10.1016/S1473-3099(13)70257-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 13 2013 11 927-935 9 045F 610 |
spelling |
10.1016/S1473-3099(13)70257-3 doi GBVA2013004000015.pica (DE-627)ELV02705943X (ELSEVIER)S1473-3099(13)70257-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Raffi, François verfasserin aut Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial 2013 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. Jaeger, Hans oth Quiros-Roldan, Eugenia oth Albrecht, Helmut oth Belonosova, Elena oth Gatell, Jose M oth Baril, Jean-Guy oth Domingo, Pere oth Brennan, Clare oth Almond, Steve oth Min, Sherene oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:13 year:2013 number:11 pages:927-935 extent:9 https://doi.org/10.1016/S1473-3099(13)70257-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 13 2013 11 927-935 9 045F 610 |
allfields_unstemmed |
10.1016/S1473-3099(13)70257-3 doi GBVA2013004000015.pica (DE-627)ELV02705943X (ELSEVIER)S1473-3099(13)70257-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Raffi, François verfasserin aut Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial 2013 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. Jaeger, Hans oth Quiros-Roldan, Eugenia oth Albrecht, Helmut oth Belonosova, Elena oth Gatell, Jose M oth Baril, Jean-Guy oth Domingo, Pere oth Brennan, Clare oth Almond, Steve oth Min, Sherene oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:13 year:2013 number:11 pages:927-935 extent:9 https://doi.org/10.1016/S1473-3099(13)70257-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 13 2013 11 927-935 9 045F 610 |
allfieldsGer |
10.1016/S1473-3099(13)70257-3 doi GBVA2013004000015.pica (DE-627)ELV02705943X (ELSEVIER)S1473-3099(13)70257-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Raffi, François verfasserin aut Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial 2013 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. Jaeger, Hans oth Quiros-Roldan, Eugenia oth Albrecht, Helmut oth Belonosova, Elena oth Gatell, Jose M oth Baril, Jean-Guy oth Domingo, Pere oth Brennan, Clare oth Almond, Steve oth Min, Sherene oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:13 year:2013 number:11 pages:927-935 extent:9 https://doi.org/10.1016/S1473-3099(13)70257-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 13 2013 11 927-935 9 045F 610 |
allfieldsSound |
10.1016/S1473-3099(13)70257-3 doi GBVA2013004000015.pica (DE-627)ELV02705943X (ELSEVIER)S1473-3099(13)70257-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Raffi, François verfasserin aut Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial 2013 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. Jaeger, Hans oth Quiros-Roldan, Eugenia oth Albrecht, Helmut oth Belonosova, Elena oth Gatell, Jose M oth Baril, Jean-Guy oth Domingo, Pere oth Brennan, Clare oth Almond, Steve oth Min, Sherene oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:13 year:2013 number:11 pages:927-935 extent:9 https://doi.org/10.1016/S1473-3099(13)70257-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 13 2013 11 927-935 9 045F 610 |
language |
English |
source |
Enthalten in Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model New York, NY volume:13 year:2013 number:11 pages:927-935 extent:9 |
sourceStr |
Enthalten in Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model New York, NY volume:13 year:2013 number:11 pages:927-935 extent:9 |
format_phy_str_mv |
Article |
bklname |
Parasitologie |
institution |
findex.gbv.de |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
authorswithroles_txt_mv |
Raffi, François @@aut@@ Jaeger, Hans @@oth@@ Quiros-Roldan, Eugenia @@oth@@ Albrecht, Helmut @@oth@@ Belonosova, Elena @@oth@@ Gatell, Jose M @@oth@@ Baril, Jean-Guy @@oth@@ Domingo, Pere @@oth@@ Brennan, Clare @@oth@@ Almond, Steve @@oth@@ Min, Sherene @@oth@@ |
publishDateDaySort_date |
2013-01-01T00:00:00Z |
hierarchy_top_id |
ELV013808834 |
dewey-sort |
3610 |
id |
ELV02705943X |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV02705943X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623185234.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1473-3099(13)70257-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013004000015.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV02705943X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1473-3099(13)70257-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Raffi, François</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jaeger, Hans</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quiros-Roldan, Eugenia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Albrecht, Helmut</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Belonosova, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gatell, Jose M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baril, Jean-Guy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Domingo, Pere</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brennan, Clare</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Almond, Steve</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Min, Sherene</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Berhane, S. ELSEVIER</subfield><subfield code="t">Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model</subfield><subfield code="d">2016</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV013808834</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:927-935</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1473-3099(13)70257-3</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2013</subfield><subfield code="e">11</subfield><subfield code="h">927-935</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
author |
Raffi, François |
spellingShingle |
Raffi, François ddc 610 bkl 44.44 Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
authorStr |
Raffi, François |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV013808834 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
610 610 DE-600 610 VZ 44.44 bkl Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
topic |
ddc 610 bkl 44.44 |
topic_unstemmed |
ddc 610 bkl 44.44 |
topic_browse |
ddc 610 bkl 44.44 |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
h j hj e q r eqr h a ha e b eb j m g jm jmg j g b jgb p d pd c b cb s a sa s m sm |
hierarchy_parent_title |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
hierarchy_parent_id |
ELV013808834 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV013808834 |
title |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
ctrlnum |
(DE-627)ELV02705943X (ELSEVIER)S1473-3099(13)70257-3 |
title_full |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
author_sort |
Raffi, François |
journal |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
journalStr |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2013 |
contenttype_str_mv |
zzz |
container_start_page |
927 |
author_browse |
Raffi, François |
container_volume |
13 |
physical |
9 |
class |
610 610 DE-600 610 VZ 44.44 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Raffi, François |
doi_str_mv |
10.1016/S1473-3099(13)70257-3 |
dewey-full |
610 |
title_sort |
once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with hiv-1 infection (spring-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
title_auth |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
abstract |
In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. |
abstractGer |
In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. |
abstract_unstemmed |
In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 |
container_issue |
11 |
title_short |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
url |
https://doi.org/10.1016/S1473-3099(13)70257-3 |
remote_bool |
true |
author2 |
Jaeger, Hans Quiros-Roldan, Eugenia Albrecht, Helmut Belonosova, Elena Gatell, Jose M Baril, Jean-Guy Domingo, Pere Brennan, Clare Almond, Steve Min, Sherene |
author2Str |
Jaeger, Hans Quiros-Roldan, Eugenia Albrecht, Helmut Belonosova, Elena Gatell, Jose M Baril, Jean-Guy Domingo, Pere Brennan, Clare Almond, Steve Min, Sherene |
ppnlink |
ELV013808834 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth oth oth oth oth oth oth |
doi_str |
10.1016/S1473-3099(13)70257-3 |
up_date |
2024-07-06T20:58:45.514Z |
_version_ |
1803864795265368064 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV02705943X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623185234.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1473-3099(13)70257-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013004000015.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV02705943X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1473-3099(13)70257-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Raffi, François</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jaeger, Hans</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quiros-Roldan, Eugenia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Albrecht, Helmut</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Belonosova, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gatell, Jose M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baril, Jean-Guy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Domingo, Pere</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brennan, Clare</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Almond, Steve</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Min, Sherene</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Berhane, S. ELSEVIER</subfield><subfield code="t">Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model</subfield><subfield code="d">2016</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV013808834</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:927-935</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1473-3099(13)70257-3</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2013</subfield><subfield code="e">11</subfield><subfield code="h">927-935</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
score |
7.399912 |